Software will aid optimizing pre-clinical data management in accordance with global standards and guidelines. Seoul, SOUTH KOREA August 4rd – Certara, Inc. （纳斯达克股票代码：CERT), a global leader in Biosimulation, today…
The prevalence of diabetes in the US is incredibly high and affects more than 10% of the population. Patients living with diabetes rely on insulin to manage their blood sugar…
DNDi Utilizing Pinnacle 21 Enterprise (P21E), Certara’s Data Science platform for Biostatistics, Data Management, and Data Standards to Streamline Clinical Data Flow PRINCETON, NJ/NAIROBI, KE, 2023 年 7 月 31 日 – Certara,…
Since 2019, the Institute for Clinical and Economic Review (ICER) has published an annual Unsupported Price Increase (UPI) Report on its “assessment on drugs that experience significant price hikes without…
While the concept of ‘Virtual Bioequivalence’ (VBE) using a combination of modelling, in vitro tests and integration of pre-existing data on systems and drugs is growing from its infancy, building confidence on…
In the world of pharmacokinetic/dynamic (PBPK/PD) modelling, compound PBPK models are incorporated into compound files that serve as a vital component for accurate predictions for virtual clinical trials. Version 22…
In September 2023, the European Medicines Agency (EMA) will reinstate their Policy 0070 requirement to publish all clinical studies submitted to the EMA for regulatory approval. After almost five years…
You are having a good day as a quality assurance professional at a small pharmaceutical company until you open an email from your company president asking for an explanation. She…
PRINCETON, N.J.— 2023 年 7 月 13 日– Certara, Inc. （纳斯达克股票代码：CERT), a global leader in biosimulation, today announced that it will release financial results for the second quarter of 2023 after the…
历史上，FDA 要求药物发现与开发项目必须包含动物试验。With the 2022 passage of the FDA Modernization Act 2.0, the definition of “nonclinical tests” conducted to support pharmaceutical…
© 2025 Certara. 保留所有权力。 | 隐私政策
